| scholarly article | Q13442814 |
| P50 | author | Amalia Gastaldelli | Q43294287 |
| Ralph A. DeFronzo | Q58689309 | ||
| Eleuterio Ferrannini | Q59193801 | ||
| P2093 | author name string | Masafumi Matsuda | |
| Andrea Mari | |||
| Yoshinori Miyazaki | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Glucose | Q37525 |
| cell function | Q95674809 | ||
| P304 | page(s) | 493-500 | |
| P577 | publication date | 2004-10-13 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | |
| P478 | volume | 90 |
| Q37107776 | A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes |
| Q37697697 | A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations |
| Q91997308 | A glucose-dependent spatial patterning of exocytosis in human β-cells is disrupted in type 2 diabetes |
| Q42106674 | A minimal C-peptide sampling method to capture peak and total prehepatic insulin secretion in model-based experimental insulin sensitivity studies |
| Q37644429 | A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment |
| Q35578281 | A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study |
| Q35684983 | A spectrum of dynamic insulin sensitivity test protocols |
| Q33488336 | Actos Now for the prevention of diabetes (ACT NOW) study |
| Q51357717 | Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. |
| Q36241454 | Advances in epidemiology and treatment of type 2 diabetes in children |
| Q36844820 | Aldehydes and disturbance of carbohydrate metabolism: some consequences and possible approaches to its normalization |
| Q60462118 | Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic |
| Q53601871 | Anti-diabetic medications: How to make a choice? |
| Q42150075 | Assessing replication and beta cell function in adenovirally-transduced isolated rodent islets |
| Q34297738 | Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin |
| Q26829445 | Assessment of pancreatic β-cell function: review of methods and clinical applications |
| Q38013003 | Assessment of β-cell function in human patients |
| Q98291959 | Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes |
| Q93119411 | Association of artificially sweetened and sugar-sweetened soft drinks with β-cell function, insulin sensitivity, and type 2 diabetes: the Maastricht Study |
| Q51367547 | Association of β-cell function and insulin sensitivity with fasting and 2-h plasma glucose in a large Chinese population. |
| Q33616844 | Associations of Dietary Glucose, Fructose, and Sucrose with β-Cell Function, Insulin Sensitivity, and Type 2 Diabetes in the Maastricht Study |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q40391316 | Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study |
| Q97682145 | Brain substrate metabolism and ß-cell function in humans: A positron emission tomography study |
| Q37692849 | Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes |
| Q34153490 | Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range |
| Q42733150 | Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function |
| Q37163530 | Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men |
| Q51031389 | Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test. |
| Q33857423 | Childhood Maltreatment Is an Independent Risk Factor for Prediabetic Disturbances in Glucose Regulation |
| Q38129446 | Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes |
| Q36268836 | Chronic stress, inflammation, and glucose regulation in U.S. Hispanics from the HCHS/SOL Sociocultural Ancillary Study |
| Q37659673 | Comparative effectiveness of liraglutide in the treatment of type 2 diabetes |
| Q48221716 | Comparison of β-Cell Function Between Overweight/Obese Adults and Adolescents Across the Spectrum of Glycemia |
| Q33530626 | DISTq: An Iterative Analysis of Glucose Data for Low-Cost, Real-Time and Accurate Estimation of Insulin Sensitivity |
| Q33962117 | DNA methylation of microRNA-375 in impaired glucose tolerance |
| Q35578244 | Dapagliflozin lowers plasma glucose concentration and improves β-cell function |
| Q34084580 | Declining beta-cell function relative to insulin sensitivity with increasing fasting glucose levels in the nondiabetic range in children |
| Q35179833 | Declining β-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. |
| Q52726650 | Delay in glucose peak time during the oral glucose tolerance test as an indicator of insulin resistance and insulin secretion in type 2 diabetes patients. |
| Q38648813 | Deterioration of insulin release rate response to glucose during oral glucose tolerance test is associated with an increased risk of incident diabetes in normal glucose tolerance subjects. |
| Q43220830 | Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study |
| Q36175793 | Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range |
| Q37186774 | Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis |
| Q39040207 | Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. |
| Q92775377 | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| Q37996460 | Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes |
| Q35696511 | Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance |
| Q33969569 | Early insulin secretory dysfunction in korean prediabetic subjects: should we change the criteria for "prediabetes?". |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q60462189 | Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training |
| Q33560177 | Ecodevelopmental contexts for preventing type 2 diabetes in Latino and other racial/ethnic minority populations |
| Q38378534 | Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin |
| Q33804747 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin |
| Q85217187 | Effects of gallic acid on brain lipid peroxide and lipid metabolism in streptozotocin‐induced diabetic Wistar rats |
| Q37138709 | Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects |
| Q51478323 | Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. |
| Q38445269 | Emerging treatments for post-transplantation diabetes mellitus |
| Q35766915 | Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study |
| Q90178371 | Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas |
| Q56889294 | Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial |
| Q35597914 | Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids |
| Q28301027 | Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion |
| Q48005781 | Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned |
| Q89656191 | Fasting glucagon concentrations are associated with longitudinal decline of β-cell function in non-diabetic humans |
| Q51492652 | Fasting-based estimates of insulin sensitivity in overweight and obesity: a critical appraisal. |
| Q42521256 | Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion |
| Q89624033 | From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options |
| Q33991613 | Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes |
| Q37429250 | Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. |
| Q42444129 | Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor |
| Q33610661 | Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control |
| Q40140158 | Hemoglobin A1c as a marker for identifying diabetes and cardiovascular risk factors: the China Health and Nutrition Survey 2009. |
| Q47929211 | High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon Hospital Health Management Center Study 8 (TOPICS 8). |
| Q44561644 | High-intensity exercise training for the prevention of type 2 diabetes mellitus. |
| Q53058978 | High-normal 2 h glucose is associated with defects of insulin secretion and predispose to diabetes in Chinese adults. |
| Q41689680 | Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis |
| Q90139193 | Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction |
| Q88103405 | Hypertension with diabetes mellitus: physiology and pathology |
| Q36597604 | ILSI Brazil International Workshop on Functional Foods: a narrative review of the scientific evidence in the area of carbohydrates, microbiome, and health |
| Q61456228 | Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents |
| Q35594627 | Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study |
| Q57035907 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes |
| Q36966443 | Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q46944971 | Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance |
| Q37531511 | Impact of obesity severity and duration on pancreatic β- and α-cell dynamics in normoglycemic non-human primates. |
| Q40543168 | Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats |
| Q47360675 | Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans |
| Q44064451 | Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects |
| Q43131881 | Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance |
| Q46887129 | Impaired beta-cell function in lean normotolerant former gestational diabetic women |
| Q51363927 | Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. |
| Q35773335 | Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes |
| Q38335305 | Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. |
| Q57663772 | Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas |
| Q37022913 | In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? |
| Q41685853 | Increased skeletal muscle capillarization enhances insulin sensitivity. |
| Q35561076 | Influence of hyperinsulinemia and insulin resistance on in vivo β-cell function: their role in human β-cell dysfunction |
| Q36842114 | Influence of maternal obesity on insulin sensitivity and secretion in offspring |
| Q37163767 | Insufficient control of blood pressure and incident diabetes |
| Q39334553 | Insulin Resistance and Mitochondrial Dysfunction. |
| Q37199318 | Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine |
| Q46264670 | Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial |
| Q48363234 | Insulin resistance and cardiovascular outcomes in the ORIGIN trial |
| Q46798133 | Insulin resistance and secretion assessment across a range of glucose tolerance from normal individuals through diabetes |
| Q45985643 | Insulin resistance versus beta-cell dysfunction in the pathogenesis of type 2 diabetes. |
| Q89677277 | Insulin resistance, beta-cell function, adipokine profiles and cardiometabolic risk factors among Chinese youth with isolated impaired fasting glucose versus impaired glucose tolerance: the BCAMS study |
| Q35995444 | Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa |
| Q34585855 | Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding |
| Q41480990 | Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls. |
| Q47755876 | Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. |
| Q41844759 | Is beta-cell failure in type 2 diabetes mellitus reversible? |
| Q36383033 | Is insulin resistance the cause of the metabolic syndrome? |
| Q39065609 | Islet inflammation in type 2 diabetes and physiology |
| Q42500046 | Lentivirus shRNA Grb10 targeting the pancreas induces apoptosis and improved glucose tolerance due to decreased plasma glucagon levels |
| Q49822604 | Lessons learned from the 1-hour post-load glucose level during the OGTT - Current screening recommendations for dysglycemia should be revised |
| Q35992959 | Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden |
| Q51784372 | Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure. |
| Q38134112 | Macrophages and islet inflammation in type 2 diabetes |
| Q57412648 | Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q22241288 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). |
| Q44864538 | Mathematical models of diabetes progression |
| Q93016700 | Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus |
| Q45941398 | Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans. |
| Q93138049 | Mechanisms of hyperinsulinaemia in apparently healthy non-obese young adults: role of insulin secretion, clearance and action and associations with plasma amino acids |
| Q31137356 | Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes |
| Q37311220 | Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents |
| Q47235131 | Microbial Regulation of Glucose Metabolism and Insulin Resistance |
| Q37889277 | Mitochondrial pathophysiology and type 2 diabetes mellitus |
| Q38038661 | Modulation of β-cell function: a translational journey from the bench to the bedside |
| Q51300770 | Myocardial glucose uptake in patients with the m.3243A > G mutation in mitochondrial DNA. |
| Q42970403 | NF-kappaB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated hemoglobin in Chinese population |
| Q38640170 | New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin |
| Q35910421 | Novel Agents for the Treatment of Type 2 Diabetes |
| Q51013056 | Nutrient infusion bypassing duodenum-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects. |
| Q38038651 | Nutrition-/diet-induced changes in gene expression in pancreatic β-cells. |
| Q33678580 | One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study |
| Q34299634 | Oral glucose tolerance test-based calculation identifies different glucose intolerance phenotypes within the impaired fasting glucose range |
| Q36426675 | Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q37505516 | Pathophysiology of prediabetes |
| Q38381360 | Pediatric drug development programs for type 2 diabetes: A review |
| Q64247839 | Performance of HbA1c versus oral glucose tolerance test (OGTT) as a screening tool to diagnose dysglycemic status in high-risk Thai patients |
| Q39413300 | Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum |
| Q39874247 | Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. |
| Q91805098 | Postprandial Insulin Response and Clearance Among Black and White Women: The Federal Women's Study |
| Q37777010 | Prediabetes: The Importance of Early Identification and Intervention |
| Q40666878 | Prediabetes: evaluation of β-cell function |
| Q51477249 | Predicting the 20-year diabetes incidence rate. |
| Q51246450 | Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. |
| Q37278256 | Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk |
| Q35612772 | Predictive Power for Type 2 Diabetes Mellitus using Dynamic Change of Metabolic Syndrome, Dynamic Change of Fasting Plasma Glucose, Metabolic Syndrome and Fasting Plasma Glucose |
| Q35541829 | Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review |
| Q26998568 | Prenatal programming of insulin secretion in intrauterine growth restriction |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q37251096 | Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates |
| Q88017549 | Prospective associations of dietary carbohydrate, fat, and protein intake with β-cell function in the CODAM study |
| Q35132429 | Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. |
| Q51168864 | Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. |
| Q46135110 | Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans |
| Q37921905 | Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus |
| Q41945969 | Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes |
| Q40955012 | Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series |
| Q51361908 | Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. |
| Q51049617 | Sugar-sweetened product consumption alters glucose homeostasis compared with dairy product consumption in men and women at risk of type 2 diabetes mellitus. |
| Q38254279 | Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions |
| Q33776764 | Target guided isolation, in-vitro antidiabetic, antioxidant activity and molecular docking studies of some flavonoids from Albizzia Lebbeck Benth. bark |
| Q37091579 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins |
| Q38268577 | The Early Diabetes Intervention Program--is early actually late? |
| Q45806588 | The Finnish Diabetes Risk Score is associated with insulin resistance but not reduced β-cell function, by classical and model-based estimates |
| Q47204205 | The Need to Calculate Target Glucose Levels When Measuring Changes in Insulin Sensitivity During Interventions for Individuals With Type 2 Diabetes |
| Q55024341 | The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. |
| Q37108880 | The clinical utility of C-peptide measurement in the care of patients with diabetes |
| Q51076251 | The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes. |
| Q35337561 | The effect of type-2-diabetes-related vascular endothelial dysfunction on skin physiology and activities of daily living |
| Q51013418 | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. |
| Q36902183 | The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? |
| Q33855031 | The pancreatic β-cell transcriptome and integrated-omics |
| Q33705046 | The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance |
| Q34718244 | The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. |
| Q34750027 | Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. |
| Q51485541 | Thiazolidinediones improve beta-cell function in type 2 diabetic patients. |
| Q48167976 | Time to glucose peak during an oral glucose tolerance test identifies prediabetes risk |
| Q37304741 | Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. |
| Q35352055 | Transcriptional activity of the islet β cell factor Pdx1 is augmented by lysine methylation catalyzed by the methyltransferase Set7/9. |
| Q35453595 | Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and antidiabetic drugs |
| Q60301930 | Treatment approach to type 2 diabetes: Past, present and future |
| Q26783350 | Treatment of prediabetes |
| Q90297811 | Two- vs one-hour glucose tolerance testing: Predicting prediabetes in adolescent girls with obesity |
| Q27694430 | Type 2 diabetes can be prevented with early pharmacological intervention |
| Q37837496 | Type 2 diabetes mellitus--current therapies and the emergence of surgical options |
| Q42576525 | Type 2 diabetes: uses of thiazolidinediones and insulin |
| Q37357372 | Validation of the BETA-2 Score: An Improved Tool to Estimate Beta Cell Function After Clinical Islet Transplantation Using a Single Fasting Blood Sample. |
| Q46639582 | Visceral fat and beta cell function in non-diabetic humans |
| Q51759642 | Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. |
| Q43642531 | Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes |
| Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
| Q42418240 | mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a Rat Model of Metabolic Syndrome |
| Q57075124 | β-Cell Failure or β-Cell Abuse? |
| Q49955808 | β-Cell Function Over Time in Adolescents With New Type 2 Diabetes and Obese Adolescents Without Diabetes |
| Q33588325 | β-Cell failure in type 2 diabetes |
| Q35922968 | β-cell dysfunction in adolescents and adults with newly diagnosed type 2 diabetes mellitus |
| Q34393402 | β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. |
Search more.